$377 Million is the total value of Cormorant Asset Management, LP's 54 reported holdings in Q2 2014. The portfolio turnover from Q1 2014 to Q2 2014 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IDRA | Exit | IDERA PHARMACEUTICALS INC | $0 | – | -400,000 | -100.0% | -0.38% | – |
| BIIB | Exit | BIOGEN IDEC INC | $0 | – | -10,000 | -100.0% | -0.70% | – |
| GERN | Exit | GERON CORP | $0 | – | -1,500,000 | -100.0% | -0.72% | – |
| PCRX | Exit | PACIRA PHARMACEUTICALS INC | $0 | – | -50,000 | -100.0% | -0.80% | – |
| PRTA | Exit | PROTHENA CORP PLC | $0 | – | -350,000 | -100.0% | -3.08% | – |
| IDIX | Exit | IDENIX PHARMACEUTICALS INC | $0 | – | -2,500,000 | -100.0% | -3.47% | – |
| ICPT | Exit | INTERCEPT PHARMACEUTICALS IN | $0 | – | -50,000 | -100.0% | -3.79% | – |
| BMRN | Exit | BIOMARIN PHARMACEUTICAL INC | $0 | – | -300,000 | -100.0% | -4.70% | – |
| CBST | Exit | CUBIST PHARMACEUTICALS INC | $0 | – | -300,000 | -100.0% | -5.05% | – |
| MDVN | Exit | MEDIVATION INC | $0 | – | -600,000 | -100.0% | -8.88% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-06-20 |
| 4 | 2024-06-13 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-13 |
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.